W.M. Meegdes

Geurts, S. M. E., Ibragimova, K. I. E., Ding, N., Meegdes, M., Erdkamp, F., Heijns, J. B., Tol, J., Vriens, B. E. P. J., Dercksen, M. W., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L., Peters, N. A. J. B., van de Wouw, A. J., Maaskant, S. A. J. G., Teeuwen-Dedroog, N. J. A., van Nijnatten, T. J. A., de Boer, M., & Tjan-Heijnen, V. C. G. (2024). Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+?metastatic breast cancer: an analysis of the SONABRE registry. Breast Cancer Research and Treatment, 205(2), 287-302. https://doi.org/10.1007/s10549-023-07235-0

Lammers, S. W. M., Meegdes, M., Vriens, I. J. H., Voogd, A. C., de Munck, L., van Nijnatten, T. J. A., Keymeulen, K. B. M. I., Tjan-Heijnen, V. C. G., & Geurts, S. M. E. (2024). Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study. ESMO Open, 9(5), Article 103008. https://doi.org/10.1016/j.esmoop.2024.103008

Lammers, S. W. M., Thurisch, H., Vriens, I. J. H., Meegdes, M., Engelen, S. M. E., Erdkamp, F. L. G., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L. M. H., Peters, N. A. J. B., Tol, J., Heijns, J. B., van de Wouw, A. J., Teeuwen, N. J. A., Geurts, S. M. E., & Tjan-Heijnen, V. C. G. (2024). The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment, 203(2), 339-349. https://doi.org/10.1007/s10549-023-07108-6

Ibragimova, K. I. E., Geurts, S. M. E., Laczkó, D., Meegdes, M., Erdkamp, F., Heijns, J. B., Tol, J., Vriens, B. E. P. J., Aaldering, K. N. A., Dercksen, M. W., Pepels, M. J. A. E., Peters, N. A. J. B., van de Winkel, L. M. H., van de Wouw, A. J., de Fallois, A., van Kats, M. A. C. E., & Tjan-Heijnen, V. C. G. (2024). Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry. Clinical Breast Cancer, 24(2), 103-111. https://doi.org/10.1016/j.clbc.2023.10.009

Meegdes, M., van der Velde, M. G. A. M., Geurts, S. M. E., van Kats, M. A. C. E., Dercksen, M. W., & Tjan-Heijnen, V. C. G. (2024). Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors. Journal of Chemotherapy, 36(4), 343-350. https://doi.org/10.1080/1120009X.2023.2279831

Ibragimova, K. I. E., Geurts, S. M. E., Meegdes, M., Erdkamp, F., Heijns, J. B., Tol, J., Vriens, B. E. P. J., Dercksen, M. W., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L., Peters, N. A. J. B., Teeuwen-Dedroog, N. J. A., Vriens, I. J. H., & Tjan-Heijnen, V. C. G. (2023). Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry. Breast Cancer Research and Treatment, 198(2), 239-251. https://doi.org/10.1007/s10549-022-06832-9

Meegdes, M., Geurts, S. M. E., Erdkamp, F. L. G., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L. M. H., Peters, N. A. J. B., Tol, J., Heijns, J. B., van de Wouw, A. J., de Fallois, A. J. O., van Kats, M. A. C. E., & Tjan-Heijnen, V. C. G. (2023). Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry. The Lancet Regional Health – Europe, 26(1), Article 100573. https://doi.org/10.1016/j.lanepe.2022.100573

Meegdes, M., Ibragimova, K. I. E., Lobbezoo, D. J. A., Vriens, I. J. H., Kooreman, L. F. S., Erdkamp, F. L. G., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L. M. H., Tol, J., Heijns, J. B., van de Wouw, A. J., Peters, N. A. J. B., Hochstenbach-Waelen, A., Smidt, M. L., Geurts, S. M. E., & Tjan-Heijnen, V. C. G. (2022). The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment, 192(2), 331-342. https://doi.org/10.1007/s10549-021-06472-5

Meegdes, M., Geurts, S. M. E., Erdkamp, F. L. G., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., Winkel, L. M. H., Teeuwen, N. J. A., Boer, M., & Tjan-Heijnen, V. C. G. (2022). The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: A study of the Dutch SONABRE Registry. International Journal of Cancer, 150(1), 124-131. https://doi.org/10.1002/ijc.33785